Digipath, Inc. (DIGP) Stock

About Digipath, Inc.

Digipath, Inc., with its subsidiaries, offers essential laboratory testing for cannabis and hemp, primarily serving Nevada's licensed medical marijuana enterprises from its base in Las Vegas. Beyond these core analytical services, the company also provides comprehensive support to the broader cannabis industry, including educational programs, professional training, and news coverage. As a dedicated testing laboratory, Digipath analyzes various products such as cannabis, cannabis-infused items, hemp, and other botanical nutraceuticals, catering to cultivators, dispensaries, caregivers, producers, patients, and end-users of these botanical goods. A critical aspect of their operations involves rigorously screening medicinal and recreational cannabis for potential contaminants. This includes checks for residual solvents, moisture content, water activity, and visual integrity, alongside identifying pesticides, a spectrum of heavy metals (like mercury, arsenic, lead, cadmium, chromium, and nickel), biological toxins (including aflatoxin and ocratoxins), and a wide array of microbial contaminants (such as E. coli, salmonella, coliforms, aspergillus, gram-negative bacteria, total aerobic bacteria, mold, and yeast). Digipath, Inc. was established in 2010 and is headquartered in Las Vegas, Nevada.

Digipath, Inc. is headquartered in US.

Digipath, Inc. (DIGP) stock trades at $0.01 with a market capitalization of $1.09M. The stock is valued at a price-to-earnings (P/E) ratio of -1.55, price-to-book of -0.60, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.01 and $0.07, and currently trades 85.7% below its 52-week high.

On profitability, Digipath, Inc. generates a return on equity (ROE) of 96.46% — well above the market average, a sign of a high-quality business, return on capital employed of 87.85%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: hyphalabs.com